Sugi Predict

Sugi Predict / Compounds / SCHEMBL873954

SCHEMBL873954

SCHEMBL873954

CC(=O)Oc1cccc(-c2nc(Cl)c3ccccc3n2)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 5/20 0.59
▸ MAPT P10636 4/20 0.59
▸ ALDH1A1 P00352 3/20 0.59
▸ ROCK2 O75116 1/20 0.55
▸ CYP1A2 P05177 10/20 0.51
▸ CYP3A4 P08684 10/20 0.51
▸ CYP2C9 P11712 5/20 0.51
▸ NR1I3 Q14994 3/20 0.51
▸ CYP2B6 P20813 2/20 0.51
▸ AHR P35869 2/20 0.51
▸ VDR P11473 1/20 0.51
▸ CYP2D6 P10635 9/20 0.49
▸ CYP2C19 P33261 7/20 0.49
▸ TSHR P16473 6/20 0.49
▸ CLK4 Q9HAZ1 5/20 0.49
▸ ATM Q13315 1/20 0.49
▸ USP2 O75604 5/20 0.48
▸ MAPK1 P28482 5/20 0.48
▸ HSD17B10 Q99714 3/20 0.48
▸ ALOX15 P16050 3/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27694078 0.83 CYP1A2 (0.72) LMNAMAPTALDH1A1CYP1A2CYP3A4
SCHEMBL961469 0.81 LMNA (0.44) LMNAMAPTALDH1A1ROCK2CYP3A4
SCHEMBL3909815 0.81 GUSB (0.44) LMNAMAPTALDH1A1TSHRATM
SCHEMBL874350 0.78 KMT2A (0.54) LMNAMAPTALDH1A1CYP3A4CYP2C9
SCHEMBL26123153 0.78 CYP1A2 (0.46) LMNAMAPTALDH1A1ROCK2CYP1A2
SCHEMBL26118180 0.77 ROCK2 (0.62) LMNAMAPTALDH1A1ROCK2CYP1A2
SCHEMBL30634518 0.77 ROCK2 (0.62) LMNAMAPTALDH1A1ROCK2CYP1A2
SCHEMBL16768514 0.76 METAP1 (0.53) LMNAALDH1A1CYP1A2CYP3A4CYP2C9
SCHEMBL17300287 0.76 NR1I3 (0.65) LMNAMAPTALDH1A1CYP1A2CYP3A4
SCHEMBL26389144 0.76 MEN1 (0.55) LMNAMAPTNR1I3HSD17B10ABCB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210017166-A1 PHARMACOKINETICALLY IMPROVED COMPOUNDS SURFACE LOGIX LLC (US) 2021-01-21 — — US disclosed
US-20210017166-A1 PHARMACOKINETICALLY IMPROVED COMPOUNDS SURFACE LOGIX LLC (US) 2021-01-21 — — US disclosed
US-10570123-B2 Pharmacokinetically improved compounds SURFACE LOGIX, LLC (US) 2020-02-25 — — US disclosed
US-10570123-B2 Pharmacokinetically improved compounds SURFACE LOGIX, LLC (US) 2020-02-25 — — US disclosed
US-20190177311-A1 PHARMACOKINETICALLY IMPROVED COMPOUNDS SURFACE LOGIX, INC. 2019-06-13 — — US disclosed
US-20190177311-A1 PHARMACOKINETICALLY IMPROVED COMPOUNDS SURFACE LOGIX, INC. 2019-06-13 — — US disclosed
US-20180072710-A1 PHARMACOKINETICALLY IMPROVED COMPOUNDS SURFACE LOGIX INC (US) 2018-03-15 — — US disclosed
US-20180072710-A1 PHARMACOKINETICALLY IMPROVED COMPOUNDS SURFACE LOGIX INC (US) 2018-03-15 — — US disclosed
US-20180072710-A1 PHARMACOKINETICALLY IMPROVED COMPOUNDS SURFACE LOGIX INC (US) 2018-03-15 — — US disclosed
US-9440961-B2 Rho-kinase inhibitors and method of preparation SURFACE LOGIX, INC. (US) 2016-09-13 — — US disclosed
WO-2012040499-A2 METABOLIC INHIBITORS SURFACE LOGIX, INC. (US) 2012-03-29 — — WO disclosed
EP-2406236-A1 RHO KINASE INHIBITORS Surface Logix, Inc. (US) 2012-01-18 — — EP disclosed
WO-2010104851-A1 RHO KINASE INHIBITORS SURFACE LOGIX, INC. (US) 2010-09-16 — — WO disclosed
US-20100144707-A1 Pharmacokinetically improved compounds SURFACE LOGIX, LLC 2010-06-10 — — US disclosed
US-20100144707-A1 Pharmacokinetically improved compounds SURFACE LOGIX, LLC 2010-06-10 — — US disclosed
US-20100144707-A1 Pharmacokinetically improved compounds SURFACE LOGIX, LLC 2010-06-10 — — US disclosed
WO-2008054599-A2 RHO KINASE INHIBITORS SURFACE LOGIX, INC. (US) 2008-05-08 — — WO disclosed
WO-2008054599-A2 RHO KINASE INHIBITORS SURFACE LOGIX, INC. (US) 2008-05-08 — — WO disclosed
EP-1865958-A2 PHARMACOKINETICALLY IMPROVED COMPOUNDS Surface Logix, Inc. (US) 2007-12-19 — — EP disclosed
WO-2006105081-A2 PHARMACOKINETICALLY IMPROVED COMPOUNDS SURFACE LOGIX, INC. (US) 2006-10-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180072710-A1 PHARMACOKINETICALLY IMPROVED COMPOUNDS ROCK2, ROCK1, RHOT2 LMNA 3392/4885MAPT 1198/4885ALDH1A1 2225/4885
US-20190177311-A1 PHARMACOKINETICALLY IMPROVED COMPOUNDS ROCK2, ROCK1, RHOT2 LMNA 3392/4885MAPT 1198/4885ALDH1A1 2225/4885
US-20210017166-A1 PHARMACOKINETICALLY IMPROVED COMPOUNDS ROCK2, ROCK1, RHOT2 LMNA 3392/4885MAPT 1198/4885ALDH1A1 2225/4885
US-20100144707-A1 Pharmacokinetically improved compounds ROCK2, ROCK1, RHOT2 LMNA 3392/4885MAPT 1198/4885ALDH1A1 2225/4885
US-10570123-B2 Pharmacokinetically improved compounds ROCK2, ROCK1, RHOT2 LMNA 3392/4885MAPT 1198/4885ALDH1A1 2225/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.